Medical Microbiology and Molecular Biology Lab., Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee, Uttrakhand, India.
J Biomol Struct Dyn. 2023 Aug-Sep;41(13):5990-6000. doi: 10.1080/07391102.2022.2099977. Epub 2022 Jul 18.
The β-lactam antibiotics are the most effective medicines for treating bacterial infections. Resistance to them, particularly through the production of β-lactamases, which can hydrolyse all kinds of β-lactams, poses a threat to their continued use. The synthesised flavone and coumarin based isoxazole derivatives have the potential to be used as broad-spectrum inhibitors of the mechanistically different serine-(SBL) and metallo-β-lactamases (MBL). The synthesised compounds were discovered as potent β-lactamase inhibitors using molecular docking and pharmacokinetic analysis. We studied the binding of chemically synthesised inhibitors to clinically significant β-lactamases of class A, B, and C using biophysical and biochemical approaches, and computational analyses. These molecules follow Lipinski's rule of five and have acceptable solubility, permeability, and oral bioavailability. These molecules were found to be non-toxic and non-carcinogenic. MIC results suggest that these molecules restore the antibiotic efficacy against class A, B, and C β-lactamases. Kinetics data showed that these molecules reduce the catalytic efficiency of clinically relevant class A, B, and C β-lactamases. Fluorescence study showed significant interaction between these flavone-/coumarin-based isoxazole derivatives and class A/B/ C β-lactamases. This study showed promising effect of these new generation compounds as broad spectrum β-lactamase inhibitors of both SBLs and MBLs.Communicated by Ramaswamy H. Sarma.
β-内酰胺类抗生素是治疗细菌感染最有效的药物。它们的耐药性,特别是通过产生β-内酰胺酶,这种酶可以水解各种β-内酰胺类药物,对它们的继续使用构成了威胁。合成的黄酮和香豆素基异恶唑衍生物有可能被用作广泛抑制机制不同的丝氨酸-(SBL)和金属-β-内酰胺酶(MBL)的抑制剂。这些化合物是通过分子对接和药代动力学分析发现的具有潜力的β-内酰胺酶抑制剂。我们使用生物物理和生化方法以及计算分析研究了化学合成抑制剂与临床重要的 A、B 和 C 类β-内酰胺酶的结合。这些分子符合 Lipinski 的五规则,具有可接受的溶解度、渗透性和口服生物利用度。这些分子被发现是无毒和非致癌的。MIC 结果表明,这些分子恢复了抗生素对 A、B 和 C 类β-内酰胺酶的疗效。动力学数据表明,这些分子降低了临床相关的 A、B 和 C 类β-内酰胺酶的催化效率。荧光研究表明,这些黄酮基/香豆素基异恶唑衍生物与 A/B/C 类β-内酰胺酶之间存在显著的相互作用。这项研究表明,这些新一代化合物作为 SBL 和 MBL 的广谱β-内酰胺酶抑制剂具有有希望的效果。由 Ramaswamy H. Sarma 交流。